9G test Cancer/Lung  

​

Outperform Competing Technologies 

· Low-dose CT(LDCT) adapted for early screening of lung cancer, but the survival rate of lung cancer was not improved at all.

· Doctors demand a product that can complement LDCT in order to increase lung cancer survival.

Doctors who have used 9G test^TM Cancer/Lung with LDCT can strongly recommend additional examination to patients suspected of stage 1~2 lung cancer.

When 9G test^TM Cancer/Lung and LDCT are serviced at the same time, increasing the survival rate for lung cancer.

​

​

· 9G test^TM Cancer/Lung and LDCT are serviced at the same time, 80% of suspected lung cancer patients will be judged normal, and 20% of lung nodules, including stage 0~1 lung cancer, will be sent to next stage, confirmed examination.

· The confirmed test included stage 0~1 lung cancer, increasing five-year survival rate.

· The purpose of the 9G test^TM Cancer/Lung is to allow doctors to request a through examination of suspected stage 1 lung cancer patients.

9G test™ Cancer/Lung was developed and commercialized using our proprietary technology published in the world’s leading journals.

 

Published Papers

1. Quantification of Cyfra 21-1 and a Cyfra 21-1-anti-Cyfra 21-1 autoantibody immune complex for detection of early stage lung Cancer. Chemm Comm. 2019. Aug 20;55(68):10060-10063. doi: 10.1039/c9cc03620b.

2. 9G test™ Cancer/Lung : A desirable Companion to LDCT for Lung Cancer Screening. Cancers 2020, 12, 3192;doi10.3390/cancers12113192.

3. Detection and Quantification of Tp53 and p53-Anti-p53 Autoantibody Immune Complex: Promising Biomarkers in Early Stage Lung Cancer Diagnosis. Biosensors 2022, 12, 127.